Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by StockNews.com to Buy

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

Other analysts have also issued research reports about the company. Truist Financial reaffirmed a “buy” rating and issued a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Finally, Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,097.05.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $3.98 during trading on Friday, hitting $1,179.31. 564,436 shares of the stock were exchanged, compared to its average volume of 474,058. Regeneron Pharmaceuticals has a 1-year low of $769.19 and a 1-year high of $1,185.09. The company has a market capitalization of $129.94 billion, a price-to-earnings ratio of 34.84, a price-to-earnings-growth ratio of 2.99 and a beta of 0.13. The company’s fifty day simple moving average is $1,070.90 and its 200-day simple moving average is $995.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the firm earned $8.79 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. Sell-side analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders sold a total of 17,731 shares of company stock valued at $18,230,142 over the last three months. Company insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Ironwood Investment Management LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $210,000. Seaport Global Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 64.2% during the second quarter. Seaport Global Advisors LLC now owns 839 shares of the biopharmaceutical company’s stock worth $882,000 after acquiring an additional 328 shares in the last quarter. Granite FO LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $893,000. Northwestern Mutual Wealth Management Co. raised its stake in Regeneron Pharmaceuticals by 16.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company’s stock valued at $4,016,000 after buying an additional 536 shares during the period. Finally, NewEdge Advisors LLC raised its stake in Regeneron Pharmaceuticals by 6.3% in the second quarter. NewEdge Advisors LLC now owns 4,368 shares of the biopharmaceutical company’s stock valued at $4,591,000 after buying an additional 260 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.